Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Fiona Watt wins prestigious Michael Mason Prize 2016.

Dr Fiona Watt, of the Kennedy Institute of Rheumatology is the winner of the prestigious Michael Mason Prize 2016 awarded by the British Society for Rheumatology, for her contributions to the field.

The award represents the increasing interest in osteoarthritis research in recent years and desire to find new ways to treat the disease: osteoarthritis remains the leading cause of joint pain and disability in the UK, and major reason for joint replacement.
- Dr Fiona Watt

Fiona is a Senior Clinical Research Fellow at NDORMS, as well as an honorary consultant rheumatologist at the Nuffield Orthopaedic Centre. Her research work focuses on human clinical studies and trials relevant to osteoarthritis within the Arthritis Research UK Centre for Osteoarthritis Pathogenesis, where she also leads the Clinical Translation theme.

Her research interest is in the early diagnosis, stratification and treatment of osteoarthritis and she is involved with a number of groups and steering committees which focus on the treatment of this condition.

Speaking of her award, Fiona says: "It is a great honour to be this year's recipient of the Michael Mason prize. The award represents the increasing interest in osteoarthritis research in recent years and desire to find new ways to treat the disease: osteoarthritis remains the leading cause of joint pain and disability in the UK, and major reason for joint replacement. Joint injury is the single greatest risk factor for developing osteoarthritis, which often affects people in mid-life.

"Our work relating to the responses of joint tissues to injury and subsequently in individuals with recent joint injury represents work over many years by myself and colleagues at the Kennedy Institute for Rheumatology. By testing discoveries from the laboratory in clinical studies, we aim to find better of ways of predicting the onset of arthritis, and developing medical treatments which can slow or prevent arthritis, and improve joint pain for people with the condition".

The Michael Mason Prize is awarded by the Heberden Committee for excellence in clinical or scientific research in the field of rheumatology. Dr Michael Mason was a renowned clinical rheumatologist, qualified from Oxford and St Bartholomew's Hospital London. His practice was in the wider aspects of rheumatology and together with Dr W S Tegner he established an associated academic professorial unit in Rheumatology in the University of London at the London Hospital Medical College. Additionally he was instrumental in the development of the Bone and Joint Research at the London Hospital Medical College.

Similar stories

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.